Skip to main content
Top
Published in: BMC Gastroenterology 1/2016

Open Access 01-12-2016 | Research article

Implementation of baby boomer hepatitis C screening and linking to care in gastroenterology practices: a multi-center pilot study

Authors: Zobair M. Younossi, Louis L. LaLuna, John J. Santoro, Flavia Mendes, Victor Araya, Natarajan Ravendhran, Lisa Pedicone, Idania Lio, Fatema Nader, Sharon Hunt, Andrei Racila, Maria Stepanova

Published in: BMC Gastroenterology | Issue 1/2016

Login to get access

Abstract

Background

Estimates suggest that only 20 % of HCV-infected patients have been identified and <10 % treated. However, baby boomers (1945-1965) are identified as having a higher prevalence of HCV which has led the Centers for Disease Control and Prevention to make screening recommendations. The aim of this study was to implement the CDC’s screening recommendations in the unique setting of gastroenterology practices in patients previously unscreened for HCV.

Methods

After obtaining patient informed consent, demographics, clinical and health-related quality of life (HRQOL) data were collected. A blood sample was screened for HCV antibody (HCV AB) using the OraQuick HCV Rapid Antibody Test. HCV AB-positive patients were tested for presence of HCV RNA and, if HCV RNA positive, patients underwent treatment discussions.

Results

We screened 2,000 individuals in 5 gastroenterology centers located close to large metropolitan areas on the East Coast (3 Northeast, 1 Mid-Atlantic and 1 Southeast). Of the screened population, 10 individuals (0.5 %) were HCV AB-positive. HCV RNA testing was performed in 90 % (9/10) of HCV AB-positive individuals. Of those, 44.4 % (4/9) were HCV RNA-positive, and all 4 (100 %) were linked to caregiver. Compared to HCV AB negative subjects, HCV AB-positive individuals tended to be black (20.0 vs. 5.2 %, p = 0.09) and reported significantly higher rates of depression: 60.0 vs. 21.5 %, p = 0.009. These individuals also reported a significantly lower HRQOL citing having more fatigue, poorer concentration, and a decreased level of energy (p < 0.05).

Discussion

Although the prevalence of HCV AB-positive was low in previously unscreened subjects screened in the gastroenterology centers, the linkage to care was very high. The sample of patients used in this study may be biased, so further studies are needed to assess the effectiveness of the CDC screening recommendations.

Conclusion

Implementation of the Baby Boomer Screening for HCV requires identifying screening environement with high prevalence of HCV+ individuals as well as an efficient process of linking them to care.
Literature
1.
go back to reference Younossi ZM, Kanwal F, Saab S, Brown KA, El-Serag HB, Kim WR, Ahmed A, Kugelmas M, Gordon SC. The impact of hepatitis C burden: an evidence-based approach. Aliment Pharmacol Ther. 2014;39(5):518–31.CrossRefPubMed Younossi ZM, Kanwal F, Saab S, Brown KA, El-Serag HB, Kim WR, Ahmed A, Kugelmas M, Gordon SC. The impact of hepatitis C burden: an evidence-based approach. Aliment Pharmacol Ther. 2014;39(5):518–31.CrossRefPubMed
2.
go back to reference Galbraith JW, Franco RA, Donnelly JP, Rodgers JB, Morgan JM, Viles AF, Overton ET, Saag MS, Wang HE. Unrecognized chronic hepatitis C virus infection among baby boomers in the emergency department. Hepatology. 2015;61(3):776–82. doi:10.1002/hep.27410. Epub 2015 Jan 28.CrossRefPubMed Galbraith JW, Franco RA, Donnelly JP, Rodgers JB, Morgan JM, Viles AF, Overton ET, Saag MS, Wang HE. Unrecognized chronic hepatitis C virus infection among baby boomers in the emergency department. Hepatology. 2015;61(3):776–82. doi:10.​1002/​hep.​27410. Epub 2015 Jan 28.CrossRefPubMed
4.
go back to reference Turner BJ, Taylor BS, Hanson, Perez ME, Hernandez L, Villarreal R, Veerapaneni P, Fiebelkorn K. Implementing hospital-based baby boomer hepatitis c virus screening and linkage to care: Strategies, results, and costs. J Hosp Med. 2015 May 29. doi: 10.1002/jhm.2376. [Epub ahead of print]. Turner BJ, Taylor BS, Hanson, Perez ME, Hernandez L, Villarreal R, Veerapaneni P, Fiebelkorn K. Implementing hospital-based baby boomer hepatitis c virus screening and linkage to care: Strategies, results, and costs. J Hosp Med. 2015 May 29. doi: 10.​1002/​jhm.​2376. [Epub ahead of print].
5.
go back to reference Morano JP, Zelenev A, Lombard A, Marcus R, Gibson BA, Altice FL. Strategies for hepatitis C testing and linkage to care for vulnerable populations: point-of-care and standard HCV testing in a mobile medical clinic. Community Health. 2014;39(5):922–34. doi:10.1007/s10900-014-9932-9.CrossRef Morano JP, Zelenev A, Lombard A, Marcus R, Gibson BA, Altice FL. Strategies for hepatitis C testing and linkage to care for vulnerable populations: point-of-care and standard HCV testing in a mobile medical clinic. Community Health. 2014;39(5):922–34. doi:10.​1007/​s10900-014-9932-9.CrossRef
9.
go back to reference Estes C, Abdel-Kareem M, Abdel-Razek W, Abdel-Sameea E, Abuzeid M, Gomaa A, Osman W, Razavi H, Zaghla H, Waked I. Economic burden of hepatitis C in Egypt: the future impact of highly effective therapies.Aliment Pharmacol Ther. 2015 Jul 22. doi: 10.1111/apt.13316. [Epub ahead of print]. Estes C, Abdel-Kareem M, Abdel-Razek W, Abdel-Sameea E, Abuzeid M, Gomaa A, Osman W, Razavi H, Zaghla H, Waked I. Economic burden of hepatitis C in Egypt: the future impact of highly effective therapies.Aliment Pharmacol Ther. 2015 Jul 22. doi: 10.​1111/​apt.​13316. [Epub ahead of print].
10.
go back to reference John-Baptiste AA, Tomlinson G, Hsu PC, Krajden M, Heathcote EJ, Laporte A, Yoshida EM, Anderson FH, Krahn MD. Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C. Am J Gastroenterol. 2009;104(10):2439–48. doi:10.1038/ajg.2009.346. Epub 2009 Jun 30.CrossRefPubMed John-Baptiste AA, Tomlinson G, Hsu PC, Krajden M, Heathcote EJ, Laporte A, Yoshida EM, Anderson FH, Krahn MD. Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C. Am J Gastroenterol. 2009;104(10):2439–48. doi:10.​1038/​ajg.​2009.​346. Epub 2009 Jun 30.CrossRefPubMed
11.
go back to reference North CS, Hong BA, Adewuyi SA, Pollio DE, Jain MK, Devereaux R, Quartey NA, Ashitey S, Lee WM, Lisker-Melman M. Hepatitis C treatment and SVR: the gap between clinical trials and real-world treatment aspirations. Gen Hosp Psychiatry. 2013;35(2):122–8. doi:10.1016/j.genhosppsych.2012.11.002. Epub 2012 Dec 6.CrossRefPubMed North CS, Hong BA, Adewuyi SA, Pollio DE, Jain MK, Devereaux R, Quartey NA, Ashitey S, Lee WM, Lisker-Melman M. Hepatitis C treatment and SVR: the gap between clinical trials and real-world treatment aspirations. Gen Hosp Psychiatry. 2013;35(2):122–8. doi:10.​1016/​j.​genhosppsych.​2012.​11.​002. Epub 2012 Dec 6.CrossRefPubMed
12.
go back to reference Younossi ZM, Stepanova M, Sulkowski M, Naggie S, Hunt SH. All Oral Therapy With Sofosbuvir Plus Ribavirin For the Treatment of Chronic Hepatitis C in Patients Co-infected With HIV (PHOTON-1 and PHOTON 2): The Impact on Patient-Reported Outcomes. J Infect Dis. 2015;212(3):367–77. doi:10.1093/infdis/jiv005. Epub 2015 Jan 12.CrossRefPubMed Younossi ZM, Stepanova M, Sulkowski M, Naggie S, Hunt SH. All Oral Therapy With Sofosbuvir Plus Ribavirin For the Treatment of Chronic Hepatitis C in Patients Co-infected With HIV (PHOTON-1 and PHOTON 2): The Impact on Patient-Reported Outcomes. J Infect Dis. 2015;212(3):367–77. doi:10.​1093/​infdis/​jiv005. Epub 2015 Jan 12.CrossRefPubMed
13.
go back to reference Bonkovsky HL, Snow KK, Malet PF, Back-Madruga C, Fontana RJ, Sterling RK, Kulig CC, Di Bisceglie AM, Morgan TR, Dienstag JL, Ghany MG, Gretch DR, HALT-C Trial Group. Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol. 2007;46(3):420–31. Epub 2006 Nov 27.CrossRefPubMedPubMedCentral Bonkovsky HL, Snow KK, Malet PF, Back-Madruga C, Fontana RJ, Sterling RK, Kulig CC, Di Bisceglie AM, Morgan TR, Dienstag JL, Ghany MG, Gretch DR, HALT-C Trial Group. Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol. 2007;46(3):420–31. Epub 2006 Nov 27.CrossRefPubMedPubMedCentral
15.
go back to reference Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, Jacobson IM, Kowdley KV, Nyberg L, Subramanian GM, Hyland RH, Arterburn S, Jiang D, McNally J, Brainard D, Symonds WT, McHutchison JG, Sheikh AM, Younossi Z, Gane EJ. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878–87. doi:10.1056/NEJMoa1214853. Epub 2013 Apr 23.CrossRefPubMed Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, Jacobson IM, Kowdley KV, Nyberg L, Subramanian GM, Hyland RH, Arterburn S, Jiang D, McNally J, Brainard D, Symonds WT, McHutchison JG, Sheikh AM, Younossi Z, Gane EJ. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878–87. doi:10.​1056/​NEJMoa1214853. Epub 2013 Apr 23.CrossRefPubMed
16.
go back to reference Poordad F, Lawitz E, Kowdley KV, Cohen DE, Podsadecki T, Siggelkow S, Heckaman M, Larsen L, Menon R, Koev G, Tripathi R, Pilot-Matias T, Bernstein B. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med. 2013;368(1):45–53. doi:10.1056/NEJMoa1208809.CrossRefPubMed Poordad F, Lawitz E, Kowdley KV, Cohen DE, Podsadecki T, Siggelkow S, Heckaman M, Larsen L, Menon R, Koev G, Tripathi R, Pilot-Matias T, Bernstein B. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med. 2013;368(1):45–53. doi:10.​1056/​NEJMoa1208809.CrossRefPubMed
17.
go back to reference Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, Shiffman ML, Lawitz E, Everson G, Bennett M, Schiff E, Al-Assi MT, Subramanian GM, An D, Lin M, McNally J, Brainard D, Symonds WT, McHutchison JG, Patel K, Feld J, Pianko S, Nelson DR, POSITRON Study, FUSION Study. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368(20):1867–77. doi:10.1056/NEJMoa1214854. Epub 2013 Apr 23.CrossRefPubMed Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, Shiffman ML, Lawitz E, Everson G, Bennett M, Schiff E, Al-Assi MT, Subramanian GM, An D, Lin M, McNally J, Brainard D, Symonds WT, McHutchison JG, Patel K, Feld J, Pianko S, Nelson DR, POSITRON Study, FUSION Study. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368(20):1867–77. doi:10.​1056/​NEJMoa1214854. Epub 2013 Apr 23.CrossRefPubMed
18.
go back to reference Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Bräu N, Buti M, Jacobson IM, Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P, ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889–98. doi:10.1056/NEJMoa1402454. Epub 2014 Apr 11.CrossRefPubMed Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Bräu N, Buti M, Jacobson IM, Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P, ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889–98. doi:10.​1056/​NEJMoa1402454. Epub 2014 Apr 11.CrossRefPubMed
19.
go back to reference Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, Lalezari J, Younes ZH, Pockros PJ, Di Bisceglie AM, Arora S, Subramanian GM, Zhu Y, Dvory-Sobol H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Sulkowski M, Kwo P, ION-2 Investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370(16):1483–93. doi:10.1056/NEJMoa1316366. Epub 2014 Apr 11.CrossRefPubMed Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, Lalezari J, Younes ZH, Pockros PJ, Di Bisceglie AM, Arora S, Subramanian GM, Zhu Y, Dvory-Sobol H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Sulkowski M, Kwo P, ION-2 Investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370(16):1483–93. doi:10.​1056/​NEJMoa1316366. Epub 2014 Apr 11.CrossRefPubMed
20.
go back to reference Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, Illeperuma A, Svarovskaia E, Brainard DM, Symonds WT, Subramanian GM, McHutchison JG, Weiland O, Reesink HW, Ferenci P, Hézode C, Esteban R, VALENCE Investigators. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370(21):1993–2001. doi:10.1056/NEJMoa1316145. Epub 2014 May 4.CrossRefPubMed Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, Illeperuma A, Svarovskaia E, Brainard DM, Symonds WT, Subramanian GM, McHutchison JG, Weiland O, Reesink HW, Ferenci P, Hézode C, Esteban R, VALENCE Investigators. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370(21):1993–2001. doi:10.​1056/​NEJMoa1316145. Epub 2014 May 4.CrossRefPubMed
21.
go back to reference Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, Shiffman ML, Schiff E, Ghalib R, Ryan M, Rustgi V, Chojkier M, Herring R, Di Bisceglie AM, Pockros PJ, Subramanian GM, An D, Svarovskaia E, Hyland RH, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Pound D, Fried MW, ION-3 Investigators. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370(20):1879–88. doi:10.1056/NEJMoa1402355. Epub 2014 Apr 10.CrossRefPubMed Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, Shiffman ML, Schiff E, Ghalib R, Ryan M, Rustgi V, Chojkier M, Herring R, Di Bisceglie AM, Pockros PJ, Subramanian GM, An D, Svarovskaia E, Hyland RH, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Pound D, Fried MW, ION-3 Investigators. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370(20):1879–88. doi:10.​1056/​NEJMoa1402355. Epub 2014 Apr 10.CrossRefPubMed
22.
go back to reference Dalgard O, Bjøro K, Ring-Larsen H, Bjornsson E, Holberg-Petersen M, Skovlund E, Reichard O, Myrvang B, Sundelöf B, Ritland S, Hellum K, Frydén A, Florholmen J, Verbaan H, North-C Group. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology. 2008;47(1):35–42.CrossRefPubMed Dalgard O, Bjøro K, Ring-Larsen H, Bjornsson E, Holberg-Petersen M, Skovlund E, Reichard O, Myrvang B, Sundelöf B, Ritland S, Hellum K, Frydén A, Florholmen J, Verbaan H, North-C Group. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology. 2008;47(1):35–42.CrossRefPubMed
24.
go back to reference Nachega JB, Parienti J, Olalekan J, Uthman A, Gross R, Dowdy DW, Sax DE, Gallant JE, Mugavero MJ, Mills EJ, Giordano TP. Lower Pill Burden and Once-Daily Antiretroviral Treatment Regimens for HIV Infection: A Meta-Analysis of Randomized Controlled Trials. Clin Infect Dis. 2014;58(9):1297–307.CrossRefPubMedPubMedCentral Nachega JB, Parienti J, Olalekan J, Uthman A, Gross R, Dowdy DW, Sax DE, Gallant JE, Mugavero MJ, Mills EJ, Giordano TP. Lower Pill Burden and Once-Daily Antiretroviral Treatment Regimens for HIV Infection: A Meta-Analysis of Randomized Controlled Trials. Clin Infect Dis. 2014;58(9):1297–307.CrossRefPubMedPubMedCentral
25.
go back to reference Kowdley KV, Lawitz E, Poordad F, et al. Safety and efficacy of interferon-free regimens of ABT-450/r, ABT-267. ABT-333 ± ribavirin in patients with chronic HCV GT1 infection: results from the Aviator study. Poster presented at the 48th Annual Meeting of the European Association for the Study of the Liver; April 24-28, 2013; Amsterdam, The Netherlands. Kowdley KV, Lawitz E, Poordad F, et al. Safety and efficacy of interferon-free regimens of ABT-450/r, ABT-267. ABT-333 ± ribavirin in patients with chronic HCV GT1 infection: results from the Aviator study. Poster presented at the 48th Annual Meeting of the European Association for the Study of the Liver; April 24-28, 2013; Amsterdam, The Netherlands.
26.
go back to reference Baran RW, Xie W, Liu Y, Cohen DE, Gooch K. Health related quality of Life (HRQoL), health state, function and wellbeing of chronic HCV patients treated with interferon-free, oral DAA regimens: patient reported outcome (PRO) results from the Aviator study. Poster presented at: 64th Annual Meeting of the American Association for the Study of Liver Disease: Nov 1-5 2013; Washington, DC. P 1113. Baran RW, Xie W, Liu Y, Cohen DE, Gooch K. Health related quality of Life (HRQoL), health state, function and wellbeing of chronic HCV patients treated with interferon-free, oral DAA regimens: patient reported outcome (PRO) results from the Aviator study. Poster presented at: 64th Annual Meeting of the American Association for the Study of Liver Disease: Nov 1-5 2013; Washington, DC. P 1113.
28.
go back to reference Scott J, Rosa K, Fu M, Cerri K, Peeters M, Beumont M, Zeuzem S, Evon DM, Gilles L. Fatigue during treatment for hepatitis C virus: results of self-reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infection. BMC Infect Dis. 2014;14(1):465. doi:10.1186/1471-2334-14-465.CrossRefPubMedPubMedCentral Scott J, Rosa K, Fu M, Cerri K, Peeters M, Beumont M, Zeuzem S, Evon DM, Gilles L. Fatigue during treatment for hepatitis C virus: results of self-reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infection. BMC Infect Dis. 2014;14(1):465. doi:10.​1186/​1471-2334-14-465.CrossRefPubMedPubMedCentral
29.
go back to reference Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV, Moroz L, Craxi A, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, De La Rosa G, Kalmeijer R, Scott J, Sinha R, Beumont-Mauviel M. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2014;384(9941):403–13. doi:10.1016/S0140-6736(14)60494-3. Epub 2014 Jun 4.CrossRefPubMed Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV, Moroz L, Craxi A, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, De La Rosa G, Kalmeijer R, Scott J, Sinha R, Beumont-Mauviel M. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2014;384(9941):403–13. doi:10.​1016/​S0140-6736(14)60494-3. Epub 2014 Jun 4.CrossRefPubMed
30.
go back to reference Stepanova M, Younossi ZM. Interferon-Free Regimens for Chronic Hepatitis C: Barriers Due to Treatment Candidacy and Insurance Coverage. Dig Dis Sci. 2015 May 19. doi: 10.1007/s10620-015-3709-6. Stepanova M, Younossi ZM. Interferon-Free Regimens for Chronic Hepatitis C: Barriers Due to Treatment Candidacy and Insurance Coverage. Dig Dis Sci. 2015 May 19. doi: 10.​1007/​s10620-015-3709-6.​
34.
go back to reference Stepanova M, Kanwal F, El-Serag H, Younossi ZM. Insurance Status and Treatment Candidacy of Hepatitis C Patients: Analysis of Population-based Data from the United States. Hepatology. 2011;53(3):737–45.CrossRefPubMed Stepanova M, Kanwal F, El-Serag H, Younossi ZM. Insurance Status and Treatment Candidacy of Hepatitis C Patients: Analysis of Population-based Data from the United States. Hepatology. 2011;53(3):737–45.CrossRefPubMed
35.
go back to reference Cohn J, Roberts T, Amorosa V, Lemoine M, Hill A. Simplified diagnostic monitoring for hepatitis C, in the new era of direct-acting antiviral treatment. Curr Opin HIV AIDS. 2015 Jul 17. [Epub ahead of print] Cohn J, Roberts T, Amorosa V, Lemoine M, Hill A. Simplified diagnostic monitoring for hepatitis C, in the new era of direct-acting antiviral treatment. Curr Opin HIV AIDS. 2015 Jul 17. [Epub ahead of print]
36.
go back to reference U.S. Department Of Health And Human Services/Centers for Disease Control and Prevention (CDC). Recommendations for Prevention and Control of Hepatitis C Virus (HCV) Infection and HCV-Related Chronic Disease. MMWR, Oct 16, 1998. Last accessed on 30 July 2015 at http://www.cdc.gov/mmwr/PDF/rr/rr4719.PDF. U.S. Department Of Health And Human Services/Centers for Disease Control and Prevention (CDC). Recommendations for Prevention and Control of Hepatitis C Virus (HCV) Infection and HCV-Related Chronic Disease. MMWR, Oct 16, 1998. Last accessed on 30 July 2015 at http://​www.​cdc.​gov/​mmwr/​PDF/​rr/​rr4719.​PDF.
37.
go back to reference Younossi ZM, Stepanova M, Afendy M, Lam BP, Mishra A. Knowledge about infection is the only predictor of treatment in patients with chronic hepatitis C. J Viral Hepat. 2013;20(8):550–5.CrossRefPubMed Younossi ZM, Stepanova M, Afendy M, Lam BP, Mishra A. Knowledge about infection is the only predictor of treatment in patients with chronic hepatitis C. J Viral Hepat. 2013;20(8):550–5.CrossRefPubMed
39.
go back to reference Galbraith JW, Donnelly JP, Franco RA, Overton ET, Rodgers JB, Wang HE. National estimates of healthcare utilization by individuals with hepatitis C virus infection in the United States. Clin Infect Dis. 2014;59(6):755–64. doi:10.1093/cid/ciu427. Epub 2014 Jun 9.CrossRefPubMedPubMedCentral Galbraith JW, Donnelly JP, Franco RA, Overton ET, Rodgers JB, Wang HE. National estimates of healthcare utilization by individuals with hepatitis C virus infection in the United States. Clin Infect Dis. 2014;59(6):755–64. doi:10.​1093/​cid/​ciu427. Epub 2014 Jun 9.CrossRefPubMedPubMedCentral
41.
go back to reference Smith B, Morgan R, Beckett G, Falk-Yetter Y, Holtzman D, Teo C, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep. 2012;61(RR-4);1–32. Smith B, Morgan R, Beckett G, Falk-Yetter Y, Holtzman D, Teo C, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep. 2012;61(RR-4);1–32.
42.
go back to reference Moyer VA. Screening for Hepatitis C Virus Infection in Adults: U.S. Preventive Services Task Force Recommendation Statement Ann Intern Med. 2013;159(5):349–58.PubMed Moyer VA. Screening for Hepatitis C Virus Infection in Adults: U.S. Preventive Services Task Force Recommendation Statement Ann Intern Med. 2013;159(5):349–58.PubMed
43.
go back to reference Ware JE, Kosinski M. Interpreting SF-36 summary health measures: a response. Qual Life Res. 2001;10(5):405–13. discussion 415-20.CrossRefPubMed Ware JE, Kosinski M. Interpreting SF-36 summary health measures: a response. Qual Life Res. 2001;10(5):405–13. discussion 415-20.CrossRefPubMed
44.
go back to reference Younossi ZM, Guyatt G, Kiwi M, Boparai N, King D. Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut. 1999;45(2):295–300.CrossRefPubMedPubMedCentral Younossi ZM, Guyatt G, Kiwi M, Boparai N, King D. Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut. 1999;45(2):295–300.CrossRefPubMedPubMedCentral
45.
go back to reference Younossi ZM, Stepanova M, Henry L. Performance and Validation of Chronic Liver Disease Questionnaire-Hepatitis C Version (CLDQ-HCV) in Clinical Trials of Patients with Chronic Hepatitis C. Value in Health 2016 (In Press). Younossi ZM, Stepanova M, Henry L. Performance and Validation of Chronic Liver Disease Questionnaire-Hepatitis C Version (CLDQ-HCV) in Clinical Trials of Patients with Chronic Hepatitis C. Value in Health 2016 (In Press).
46.
go back to reference Webster K, Odom L, Peterman A, et al. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Validation of version 4 of the core questionnaire. Qual Life Res. 1999;8(7):604. Webster K, Odom L, Peterman A, et al. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Validation of version 4 of the core questionnaire. Qual Life Res. 1999;8(7):604.
47.
go back to reference Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmaco Economics. 1993;4:353–65.CrossRef Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmaco Economics. 1993;4:353–65.CrossRef
49.
go back to reference Wedemeyer H, Duberg AS, Buti M, Rosenberg WM, Frankova S, Esmat G, Örmeci N, et al. Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat. 2014;21 Suppl 1:60–89. 10.1111/jvh.12249.CrossRefPubMed Wedemeyer H, Duberg AS, Buti M, Rosenberg WM, Frankova S, Esmat G, Örmeci N, et al. Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat. 2014;21 Suppl 1:60–89. 10.​1111/​jvh.​12249.CrossRefPubMed
50.
go back to reference Razavi H, Bruggmann P, Wedemeyer H, Dore G. Response to letter to the editor: Strategies to reduce HCV disease burden and HCV transmission need different models, as what works for end-stage liver disease may not work for HCV prevalence: a comment on the results presented in JVH Special Issue. J Viral Hepat. 2014;21(12):e169–70. doi:10.1111/jvh.12339. Epub 2014 Sep 29.CrossRefPubMed Razavi H, Bruggmann P, Wedemeyer H, Dore G. Response to letter to the editor: Strategies to reduce HCV disease burden and HCV transmission need different models, as what works for end-stage liver disease may not work for HCV prevalence: a comment on the results presented in JVH Special Issue. J Viral Hepat. 2014;21(12):e169–70. doi:10.​1111/​jvh.​12339. Epub 2014 Sep 29.CrossRefPubMed
51.
go back to reference Rodger AJ, Jolley D, Thompson SC, Lanigan A, Crofts N. The impact of diagnosis of hepatitis C virus on quality of life. Hepatology. 1999;30(5):1299–301.CrossRefPubMed Rodger AJ, Jolley D, Thompson SC, Lanigan A, Crofts N. The impact of diagnosis of hepatitis C virus on quality of life. Hepatology. 1999;30(5):1299–301.CrossRefPubMed
52.
go back to reference Loria A, Doyle K, Weinstein AA, Winter P, Escheik C, Price J, Wang L, Birerdinc A, Baranova A, Gerber L, Younossi ZM. Multiple Factors Predict Physical Performance in People with Chronic Liver Disease. Am J Phys Med Rehabil. 2014 Jan 6. [Epub ahead of print]. Loria A, Doyle K, Weinstein AA, Winter P, Escheik C, Price J, Wang L, Birerdinc A, Baranova A, Gerber L, Younossi ZM. Multiple Factors Predict Physical Performance in People with Chronic Liver Disease. Am J Phys Med Rehabil. 2014 Jan 6. [Epub ahead of print].
53.
go back to reference Kallman J, O’Neil MM, Larive B, Boparai N, Calabrese L, Younossi ZM. Fatigue and health-related quality of life (HRQOL) in chronic hepatitis C virus infection. Dig Dis Sci. 2007;52(10):2531–9. Epub 2007 Apr 4.CrossRefPubMed Kallman J, O’Neil MM, Larive B, Boparai N, Calabrese L, Younossi ZM. Fatigue and health-related quality of life (HRQOL) in chronic hepatitis C virus infection. Dig Dis Sci. 2007;52(10):2531–9. Epub 2007 Apr 4.CrossRefPubMed
54.
go back to reference Boscarino JA1, Lu M, Moorman AC, Gordon SC, Rupp LB, Spradling PR, Teshale EH, Schmidt MA, Vijayadeva V, Holmberg SD. Predictors of poor mental and physical health status among patients with chronic hepatitis C infection: The chronic hepatitis cohort study (CHeCS). Hepatology. 2014 Sep 9. doi: 10.1002/hep.27422. [Epub ahead of print]. Boscarino JA1, Lu M, Moorman AC, Gordon SC, Rupp LB, Spradling PR, Teshale EH, Schmidt MA, Vijayadeva V, Holmberg SD. Predictors of poor mental and physical health status among patients with chronic hepatitis C infection: The chronic hepatitis cohort study (CHeCS). Hepatology. 2014 Sep 9. doi: 10.​1002/​hep.​27422. [Epub ahead of print].
Metadata
Title
Implementation of baby boomer hepatitis C screening and linking to care in gastroenterology practices: a multi-center pilot study
Authors
Zobair M. Younossi
Louis L. LaLuna
John J. Santoro
Flavia Mendes
Victor Araya
Natarajan Ravendhran
Lisa Pedicone
Idania Lio
Fatema Nader
Sharon Hunt
Andrei Racila
Maria Stepanova
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2016
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-016-0438-z

Other articles of this Issue 1/2016

BMC Gastroenterology 1/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.